Treatment of NSCLC: Best Practices from the University of Kansas Cancer Center and Satellites : Episode 13
Case 1: 72-Year-Old Former Smoker with Stage-IIIA NSCLC and PD-L1 of 90%
Gregory Gan, MD, presents Case 1 involving a 72-year-old former smoker with Stage-IIIA NSCLC and a PD-L1 level of 90%, initiating a discussion on the treatment and management of the case.
EP: 1.Available Treatment Options for Patients With Stage-III Resectable NSCLC
EP: 2.Determining Eligibility for Surgical Resection in NSCLC
EP: 3.Expert Perspectives on Perioperative Immunotherapy in Resectable Stage-III NSCLC
EP: 4.Treatment Approaches for Resectable Stage-III NSCLC in the Adjuvant Setting
EP: 5.Treatment Strategies for NSCLC Following Progression on Adjuvant Immunotherapy
EP: 6.Approaches to Treatment and Staging in Unresectable NSCLC
EP: 7.Sequential and Concurrent Chemoradiotherapy in Unresectable Stage-III NSCLC
EP: 8.Expert Insights on Adjuvant Immunotherapy in Unresectable Stage-III NSCLC
EP: 9.Managing Stage-III NSCLC with Actionable EGFR or ALK Mutations
EP: 10.The Potential Role of Combination Adjuvant Immunotherapy in NSCLC
EP: 11.Insights into Strategies Using Concurrent Immunotherapy with Chemoradiotherapy
EP: 12.Clinical Pearls for Treating NSCLC: Insights from Experts at the University of Kansas
Now Viewing
EP: 13.Case 1: 72-Year-Old Former Smoker with Stage-IIIA NSCLC and PD-L1 of 90%
EP: 14.Case 2: 82-Year-Old Former Smoker with Poorly Differentiated Lung Adenocarcinoma and PD-L1 of 85%
EP: 15.Case 3: 70-Year-Old Former Smoker with Stage IIIB NSCLC with PD-L1 10%
EP: 16.Case 4: 71-Year-Old Diagnosed with Stage IIIA NSCLC Experiencing Pneumonitis After Chemo-IO Treatment
EP: 17.A Multidisciplinary Approach to Treating Resectable NSCLC
Recent Videos
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
